News and analysis on medical technology
FDA clearedFDA cleared. Stage 4 of 4 (Authorized)

FDA Clears SurGenTec's ION-C Navigation Instruments for Cervical Facet Fixation

The locators, drill and inserter are designed to work with Medtronic's StealthStation S8 when placing SurGenTec's ION-C facet implants in the neck.

By News DeskMay 29, 20262 min read
Plastic model of the neck vertebrae and nerves viewed from behind
An anatomical model of the cervical spine seen from behind. Not the ION-C system described in this article. John Campbell, CC BY 2.0, via Wikimedia Commons · CC BY 2.0
FDA cleared510(k) · K260329FDA cleared. Stage 4 of 4 (Authorized)

The FDA cleared this device through the 510(k) pathway, which finds it substantially equivalent to a device already on the market. Clearance is not the same as approval.

Key points

  • The FDA cleared SurGenTec's ION-C Navigation Instruments under 510(k) K260329 on May 22, 2026; the clearance was reported on May 29.
  • The instruments help surgeons locate the cervical facet joint in open or minimally invasive procedures and are designed for use with the Medtronic StealthStation System S8.
  • The 510(k) summary lists sterilization, biocompatibility and engineering analyses as the performance testing, and requires fluoroscopy to confirm final implant placement.

The US Food and Drug Administration has cleared navigation instruments for SurGenTec's ION-C posterior cervical facet fixation implant, letting surgeons use the Boca Raton, Florida, company's system with Medtronic's StealthStation navigation platform, ORTHOWORLD reported on May 29.

The FDA's 510(k) database lists the clearance as K260329, a traditional 510(k) for the ION-C Navigation Instruments, received on January 30, 2026, with a substantially equivalent decision on May 22. The device is classified as an orthopedic stereotaxic instrument under product code OLO and was reviewed by the orthopedic panel.

What the clearance covers

According to the clearance letter and 510(k) summary, the instruments are intended to be used with ION-C System facet implants during spinal surgery "to assist the surgeon in precisely locating anatomical structures, specifically the cervical facet joint, in either open or minimally invasive procedures." They are designed specifically for the Medtronic StealthStation System S8, and the summary states: "Fluoroscopy must be used to confirm final implant placement."

The set consists of locators, a drill and an inserter, each meant to be used with a Medtronic NavLock Array, and is supplied sterile or non-sterile. SurGenTec cited the CORUS Navigation Access System as the primary predicate, with the Rialto SI Fusion System and a set of navigated disc preparation instruments as additional predicates. The summary says the instruments share the predicates' intended use, technology, critical geometry and materials.

Performance testing listed in the summary consists of sterilization validation, biocompatibility assessments and engineering analyses of critical geometry. The summary does not list clinical testing.

The implant and the company's pitch

ION-C is a posterior cervical facet fixation implant used in neck fusion procedures. As reported by ORTHOWORLD, SurGenTec describes it as having a zero-profile design and controlled drill-to-implant geometry intended to support non-impact placement and implant depth accuracy, and to help keep the facet joint in a neutral position during insertion.

The company said the navigation instruments are intended to support implant placement and surgical workflow efficiency, according to ORTHOWORLD. Those are the company's descriptions of the design's intent, not findings from the FDA review.

SurGenTec did not give pricing or a launch date for the ION-C navigation instruments in the material reported by ORTHOWORLD.

Sources

  1. SurGenTec Earns 510(k) for ION-C Navigation Instruments, ORTHOWORLD, May 29, 2026
  2. 510(k) K260329: Ion-C Navigation Instruments (database record), US Food and Drug Administration, May 22, 2026
  3. K260329 clearance letter and 510(k) summary, US Food and Drug Administration, May 22, 2026